search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Methylfenidaat afbouw studie bij kinderen


- candidate number22348
- NTR NumberNTR5252
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR16-jun-2015
- Secondary IDsNL49436.042.14 
- Public TitleMethylfenidaat afbouw studie bij kinderen
- Scientific TitleA multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate
- ACRONYMMethylfenidaat Afbouw Studie bij Kinderen (MASK)
- hypothesisWe will test the hypothesis that ongoing use of methylphenidate is superior to placebo with regard to ADHD symptom severity in children and adolescents who have used methylphenidate for two years or longer.
- Healt Condition(s) or Problem(s) studiedADHD, Methylphenidat, Long term results
- Inclusion criteriaIn order to be eligible to participate in this study, a subject must meet all of the following criteria:
• Children between the ages of eight to eighteen, any ethnicity or cultural background.
• Children with their first prescription of any form of methylphenidate at least two years ago.
• Children who are for at least the last four weeks the subject has been using methylphenidate in the form of Concerta 36 mg or 54 mg.
• Children with an IQ > 70 (based on a previous IQ test or attending regular education).
• Parents (or the legal guardian) and children (≥ twelve years) have provided informed consent to participate in the study.
- Exclusion criteriaExcluded from participation in this study will be:
• Children who have not been using of methylphenidate for a continuous period > 2 months during the last two years.
• Children of parents who are planning to start new psychosocial or pharmacological therapies during the blinded period.
• Children and or parents who are unable to understand or comply with the protocol.
• Children who have any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blinding[default]
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-sep-2015
- planned closingdate31-okt-2017
- Target number of participants120
- InterventionsThe participating subjects will be randomized (ratio 1:1) to either continued use of methylphenidate or to placebo during seven weeks. Withdrawal will be gradually over a period of three weeks, followed by four weeks of complete placebo. There will be three visits, at baseline, after four weeks and after seven weeks. After six months there will be a follow up by telephone.
- Primary outcomeADHD-DSM-5 RS
- Secondary outcomeRating scales
• Clinical Global Impression Scale of Improvement (CGI-I).
• Criteria of Oppositional Defiant Disorder (ODD)
• Side en withdrawal effects based on adapted version of the Barkley Side Effect Rating scale (BSERS).
• Sleep Disturbances Scale for Children (SDSC)
• Appetite of the child
• Retrospective Overt Aggression Scale (R-MOAS)
• Kindl-R
• Parental Stress Scale (PSS)
• Family atmosphere questions
• Parental Frustrations Questionnaire (PFQ)
• Child Depression Inventory (CDI)
• Strength and Difficulties Questionnaire (SDQ).
• Conners Teacher Rating Scale-Revised: short form (CTRS-R:S).

physical measures
• weight
• height
• Blood pressure
• Pulse

Biomarkers
• Blood draw (ferritin, zinc)

Neuropsychological tests
• Amsterdam Neuropsychological Tasks (three subtests)

Mediators/predictors
• treatment history, history and compliance.

Child factors
• sex, age, ethnicity and school type
• estimation of IQ
• Psychiatric diagnoses
• Tanner stage + some questions of Physical Development Scale (PDS)
• Temperament (Behavioural Avoidance and Inhibition Scale [BISBAS], Inventory of Callous and Unemotional traits [ICU], Brief Sensation Seeking Scale [BSSS])
• DNA (blood draw)
• Cortisol from hair
• Stressful events

Parental factors
• Socio-economic status
• Egna Minnen Betrδffende Uppfostran (EMBU)
• Adult ADHD Rating scale (AARS)
• Parenting Sense of Competence Scale (PSOC)
• Maudsley Marital Questionnaire (MMQ)(subschale Marital adjustment)
- Timepointsbaseline
after four weeks
after seven weeks
Blind will be broken
fully natural follow up after six months
- Trial web site
- statusplanned
- CONTACT FOR PUBLIC QUERIESMsc A.F.M. Matthijssen
- CONTACT for SCIENTIFIC QUERIESMsc A.F.M. Matthijssen
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD16-jun-2015 - 16-aug-2015


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl